Presentations An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors
Presentations Rational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function
Presentations Accelerating Targeted Protein Degrader Discovery with Automated and Integrated Direct-To-Biology Screening
Presentations Latest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies